Crinetics Pharmaceuticals (CRNX) AI Stock Analysis

• Market Cap: $3.14B
• Dividend Yield: N/A
• Average Volume (3M): 952.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.56
• Revenue Growth: N/A
• EPS Growth: -9.10%
• Country: US
• Employees: 437
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -1.23
• Shares Outstanding: 94,175,995
• 10 Day Avg. Volume: 968,666
• 30 Day Avg. Volume: 952,741
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.49
• Enterprise Value/Revenue: 1.11K
• Enterprise Value/Gross Profit: -10.41K
• Enterprise Value/Ebitda: -3.69
• 1Y Price Target: $71.09
• Price Target Upside: 107.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12

• Rating: 52 Neutral
• Price Target: $31.00 ▼(-9.49% Downside)

Crinetics Pharmaceuticals' overall stock score is primarily influenced by its financial challenges, including persistent losses and cash flow issues. While technical indicators are neutral, the valuation is negatively impacted by ongoing losses. Positive developments from the earnings call and corporate events provide some optimism, but the financial instability remains a significant concern.

Positive Factors

Market Potential

Crinetics is positioned to shift from a late-stage development company to a fully integrated commercial organization.

Product Advantage

Many called paltusotine a game-changer in acromegaly compared to the current standard-of-care.

Product Launch

The company continues to prepare for its first commercial launch of Palsonify to treat acromegaly ahead of the PDUFA target action date.

Negative Factors

Competition

Paltusotine's lead indication is acromegaly where SRLs are SOC, but fail to provide durable disease control and require painful injections.

Regulatory Approval

Crinetics is approaching its September 25 PDUFA for Palsonify (paltusone) in acromegaly, following NDA acceptance in December of last year on the back of positive Phase 3 PATHFNDR-1 and PATHFNDR-2 results.

Safety Concerns

Management reiterated comfort in atumelnant’s safety profile, despite a single case of AST/ALT elevations in the 120mg cohort, citing the growing body of clinical experience.

Crinetics Pharmaceuticals Business Overview & Revenue Model

Company Description

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for rare endocrine diseases and other unmet medical needs. The company operates primarily in the biotechnology sector, concentrating on the discovery and development of small molecule drugs that target specific receptor pathways. Its core products include investigational drugs such as paltusotine, aimed at treating conditions like acromegaly and Cushing's disease, as well as other pipeline candidates addressing various hormonal disorders.

How the Company Makes Money

Crinetics Pharmaceuticals generates revenue primarily through the development and commercialization of its drug candidates. The company may earn revenue from licensing agreements with larger pharmaceutical partners, who may fund the development and marketing of its products in exchange for a share of future sales or milestone payments. Additionally, Crinetics could receive grants or funding from governmental and non-governmental organizations for research purposes. Furthermore, successful clinical trials leading to regulatory approvals can increase the company's valuation and attract investment, thus contributing to its overall financial health.

Crinetics Pharmaceuticals Financial Statement Overview

Summary

Crinetics Pharmaceuticals faces significant financial challenges, with persistent operational losses and cash flow issues. While recent financing has strengthened the cash position, the company's ability to generate sustainable revenue and profit remains unproven. The balance sheet shows improvement, but historical financial instability highlights the need for caution.

Income Statement

Crinetics Pharmaceuticals has experienced fluctuating revenue with a decline from 2022 to 2023, followed by a sharp drop in 2024. The gross profit margin is consistently high, but net losses persist, indicating ongoing profitability challenges. Negative EBIT and EBITDA margins reflect operational inefficiencies.

Balance Sheet

The company shows a strong equity position with substantial cash reserves and minimal debt. However, negative stockholders' equity in earlier years indicates past financial distress. Current liabilities are relatively low, but the debt-to-equity ratio is a concern due to historical negative equity.

Cash Flow

Operating cash flow remains negative, highlighting potential liquidity challenges. Free cash flow is also consistently negative, though recent financing activities have bolstered cash reserves. Stability in cash flow remains a concern with ongoing operational losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.39M	1.04M	4.01M	4.74M	1.08M	71.00K
Gross Profit	-149.00K	1.04M	4.01M	3.35M	-184.00K	-56.93M
EBITDA	-420.58M	-338.85M	-221.51M	-166.90M	-106.78M	-72.59M
Net Income	-369.83M	-298.41M	-214.53M	-163.92M	-107.64M	-72.86M
Balance Sheet
Total Assets	1.29B	1.43B	635.35M	352.18M	351.01M	183.44M
Cash, Cash Equivalents and Short-Term Investments	1.20B	1.35B	558.55M	334.43M	333.71M	170.88M
Total Debt	49.94M	51.72M	51.73M	3.08M	3.07M	4.01M
Total Liabilities	118.05M	109.79M	96.25M	35.85M	19.07M	14.53M
Stockholders Equity	1.17B	1.32B	539.11M	316.33M	331.94M	168.92M
Cash Flow
Free Cash Flow	-307.80M	-229.81M	-171.00M	-116.86M	-89.02M	-62.21M
Operating Cash Flow	-301.80M	-225.97M	-166.31M	-115.20M	-88.59M	-62.03M
Investing Cash Flow	-569.49M	-574.82M	-200.41M	-173.98M	-56.48M	217.00K
Financing Cash Flow	622.86M	1.01B	388.94M	121.96M	252.68M	114.57M

Crinetics Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 34.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRNX, the sentiment is Positive. The current price of 34.25 is above the 20-day moving average (MA) of 30.25, above the 50-day MA of 30.25, and below the 200-day MA of 36.62, indicating a neutral trend. The MACD of 0.93 indicates Negative momentum. The RSI at 66.49 is Neutral, neither overbought nor oversold. The STOCH value of 90.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRNX.

Crinetics Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACAD	73 Outperform	$4.33B	19.33	33.18%	―	14.41%	627.78%
APLS	58 Neutral	$3.56B	―	-108.49%	―	20.02%	33.45%
VKTX	53 Neutral	$2.98B	―	-19.99%	―	―	-63.73%
CRNX	52 Neutral	$3.14B	―	-36.94%	―	―	-9.10%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
SRRK	50 Neutral	$3.18B	―	-172.08%	―	―	-29.50%
IMVT	45 Neutral	$2.63B	―	-77.58%	―	―	-48.38%

Crinetics Pharmaceuticals Corporate Events

Crinetics Pharmaceuticals Presents at ENDO 2025 Meeting

On June 30, 2025, Crinetics Pharmaceuticals announced that it will present eight abstracts from its clinical development programs at the Endocrine Society’s Annual Meeting, ENDO 2025, in San Francisco. The presentations will include long-term efficacy and safety data on PALSONIFY for acromegaly, results from a Phase 2 trial of atumelnant for congenital adrenal hyperplasia, and early-stage data on CRN12755 for Graves’ hyperthyroidism. These developments highlight Crinetics’ commitment to addressing unmet needs in endocrine disorders and reinforce its position as a leader in endocrine-focused pharmaceutical innovation.

Crinetics Pharmaceuticals Unveils Promising Preclinical Pipeline

On June 26, 2025, Crinetics Pharmaceuticals held a Research and Development Day in New York, presenting updates on its preclinical pipeline. Key highlights included the development of CRN12755 for Graves’ disease, CRN10329 for polycystic kidney disease, and CRN09682 for neuroendocrine tumors. The event showcased promising preclinical data and outlined strategic plans for clinical trials, indicating potential advancements in treatment options for these conditions.

Crinetics Pharmaceuticals Holds Annual Stockholders Meeting

At the annual meeting of Crinetics Pharmaceuticals‘ stockholders held on June 11, 2025, key decisions were made, including the election of three Class I directors for three-year terms, the ratification of BDO USA, P.C. as the independent accounting firm, and the approval of executive compensation. These decisions reflect strong shareholder support and are likely to influence the company’s strategic direction and governance structure.